177 related articles for article (PubMed ID: 36866788)
1. Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR-TKI in non-small cell lung cancer patients with EGFR mutation: A multicenter retrospective study.
Hata T; Sakaguchi C; Hirano K; Kobe H; Ishida M; Nakano T; Tachibana Y; Tamiya N; Shiotsu S; Takeda T; Yamada T; Yokoyama T; Tsuchiya M; Nagasaka Y
Thorac Cancer; 2023 Apr; 14(11):1004-1011. PubMed ID: 36866788
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).
Watanabe S; Furuya N; Nakamura A; Shiihara J; Nakachi I; Tanaka H; Nakao M; Minato K; Seike M; Sasaki S; Kisohara A; Takeuchi S; Honda R; Takamura K; Kagamu H; Yoshimura K; Kobayashi K; Kikuchi T
Eur J Cancer; 2024 Jan; 197():113469. PubMed ID: 38061214
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance.
Li Y; Jiang H; Qian F; Chen Y; Zhou W; Zhang Y; Lu J; Lou Y; Han B; Zhang W
Front Immunol; 2023; 14():1161718. PubMed ID: 37266427
[TBL] [Abstract][Full Text] [Related]
4. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
Reck M; Mok TSK; Nishio M; Jotte RM; Cappuzzo F; Orlandi F; Stroyakovskiy D; Nogami N; Rodríguez-Abreu D; Moro-Sibilot D; Thomas CA; Barlesi F; Finley G; Lee A; Coleman S; Deng Y; Kowanetz M; Shankar G; Lin W; Socinski MA;
Lancet Respir Med; 2019 May; 7(5):387-401. PubMed ID: 30922878
[TBL] [Abstract][Full Text] [Related]
5. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Socinski MA; Jotte RM; Cappuzzo F; Orlandi F; Stroyakovskiy D; Nogami N; Rodríguez-Abreu D; Moro-Sibilot D; Thomas CA; Barlesi F; Finley G; Kelsch C; Lee A; Coleman S; Deng Y; Shen Y; Kowanetz M; Lopez-Chavez A; Sandler A; Reck M;
N Engl J Med; 2018 Jun; 378(24):2288-2301. PubMed ID: 29863955
[TBL] [Abstract][Full Text] [Related]
6. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With
Park S; Kim TM; Han JY; Lee GW; Shim BY; Lee YG; Kim SW; Kim IH; Lee S; Kim YJ; Park JH; Park SG; Lee KH; Kang EJ; Kim JW; Shin SH; Ock CY; Nam BH; Lee J; Jung HA; Sun JM; Lee SH; Ahn JS; Ahn MJ
J Clin Oncol; 2024 Apr; 42(11):1241-1251. PubMed ID: 37861993
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in
West HJ; McCleland M; Cappuzzo F; Reck M; Mok TS; Jotte RM; Nishio M; Kim E; Morris S; Zou W; Shames D; Das Thakur M; Shankar G; Socinski MA
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190375
[TBL] [Abstract][Full Text] [Related]
8. Correlation between the qualification for bevacizumab use and the survival of patients with non-small cell lung cancer harboring the epidermal growth factor receptor mutation: a retrospective analysis.
Hakozaki T; Okuma Y; Hashimoto K; Hosomi Y
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2555-2564. PubMed ID: 31350622
[TBL] [Abstract][Full Text] [Related]
9. IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.
Nogami N; Barlesi F; Socinski MA; Reck M; Thomas CA; Cappuzzo F; Mok TSK; Finley G; Aerts JG; Orlandi F; Moro-Sibilot D; Jotte RM; Stroyakovskiy D; Villaruz LC; Rodríguez-Abreu D; Wan-Teck Lim D; Merritt D; Coleman S; Lee A; Shankar G; Yu W; Bara I; Nishio M
J Thorac Oncol; 2022 Feb; 17(2):309-323. PubMed ID: 34626838
[TBL] [Abstract][Full Text] [Related]
10. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
[TBL] [Abstract][Full Text] [Related]
12. NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy.
Trummer A; Bethge A; Dickgreber N; Dittrich I; Golpon H; Hoffknecht P; Overbeck TR; Wesseler C; Reck M
Lung Cancer; 2022 Dec; 174():141-145. PubMed ID: 36402005
[TBL] [Abstract][Full Text] [Related]
13. A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival.
Zhang CY; Sun H; Su JW; Chen YQ; Zhang SL; Zheng MY; Li YF; Huang J; Zhang C; Tai ZX; Cai M; Zhang XC; Su J; Xu CR; Yan HH; Chen HJ; Wu YL; Yang JJ
Lung Cancer; 2023 Jan; 175():68-78. PubMed ID: 36473332
[TBL] [Abstract][Full Text] [Related]
14. A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study.
Hayashi H; Chiba Y; Sakai K; Fujita T; Yoshioka H; Sakai D; Kitagawa C; Naito T; Takeda K; Okamoto I; Mitsudomi T; Kawakami Y; Nishio K; Nakamura S; Yamamoto N; Nakagawa K
Clin Lung Cancer; 2017 Nov; 18(6):719-723. PubMed ID: 28623122
[TBL] [Abstract][Full Text] [Related]
15. The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study.
Yin X; Liu X; Ren F; Meng X
Cancer Immunol Immunother; 2024 May; 73(7):134. PubMed ID: 38758372
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI's: Exploration of efficacy of unselected treatment in a multicenter cohort study.
Steendam CMJ; Ernst SM; Badrising SK; Paats MS; Aerts JGJV; de Langen AJ; Dingemans AC
Lung Cancer; 2023 Jul; 181():107248. PubMed ID: 37216839
[TBL] [Abstract][Full Text] [Related]
17. Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.
Tseng YH; Tseng YC; Lin YH; Lee YC; Perng RP; Whang-Peng J; Chen YM
Oncologist; 2015 Jul; 20(7):758-66. PubMed ID: 26054633
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab for the better treatment of EGFR-mutant T790M-negative advanced lung adenocarcinoma patients than dual treatment of pemetrexed plus platinum after tyrosine kinase inhibitor treatment failure.
Lu Z; Ye M; Sun T; Wu S; Lin Z; Zhang X; Rao D; Zhang D; Ke Y; Chen Z
Ann Palliat Med; 2022 Jun; 11(6):2100-2109. PubMed ID: 35817745
[TBL] [Abstract][Full Text] [Related]
19. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
20. EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis.
Tsai JS; Su PL; Yang SC; Chang CC; Lin CY; Yen YT; Tseng YL; Lai WW; Lin CC; Su WC
J Formos Med Assoc; 2021 Sep; 120(9):1729-1739. PubMed ID: 33865672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
